Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: IgA Nephropathy (IgAN)

In brief

Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN

Key facts

Study ID

NCT07390123

Run by

Haisco Pharmaceutical Group Co., Ltd.

People needed

370

Starts

2026-04-07

Expected to finish

2028-07-01

Last updated by the study team

2026-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have signed and dated an IRB/IEC approved written informed consent form.Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, tumor biopsies, and other requirements of the study.
• Female and male patients above 18 years of age.
• Patients must weigh at least 35 kg to participate in the study, and must have a body mass index (BMI) below 35 kg/m2. BMI = Body weight (kg) / [Height (m)]2
• Subjects with a biopsy-verified IgA nephropathy and where the biopsy was performed within the prior ten years.
• 24h-UPCR ≥0.75g/g or 24h-UPE≥1.0g/24h at screening.
• Measured Glomerular Filtration Rate (GFR) or estimated GFR (using the CKD-EPI formula 2021) ≥30 mL/min per 1.73 m2.For patients with eGFR* 20 to <30ml/min/1.73m2, a qualifying biopsy performed in two years.

You may not qualify if…

• Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 90 days, whichever is longer.
• All transplanted patients (any organ, including bone marrow).
• History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer).
• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study.
• Pregnant or nursing (lactating) women.
• Plasma donation (≥ 400mL) within 12 weeks prior to first dosing.

Where it is running

• Huangshan City People's Hospital — Huangshan City, Anhui, China (enrolling)
• The Second Affiliated Hospital of Wannan Medical College — Wuhu, Anhui, China (enrolling)
• Peking University First Hospital — Beijing, Beijing Municipality, China (enrolling)
• Zhanjiang Central Hospital — Zhanjiang, Guangdong, China (enrolling)
• Xiangya Hospital of Central South University — Changsha, Hunan, China (enrolling)
• The Second Hospital of Jilin University — Changchun, Jilin, China (enrolling)
• Linyi City People Hospital — Linyi, Shandong, China (enrolling)
• Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine — Shanghai, Shanghai Municipality, China (enrolling)
• Xijing Hospital — Xi’an, Shanxi, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.